|
Session 35
Oral Abstracts
Complications of Antiretroviral Therapy and HIV
Wednesday, 10 am - 12:30 pm
Room: Ballroom 5-6 |
Moderators: |
Paul Weidle
CDC, Atlanta, GA, US
Constance Benson
Univ of California, San Diego, US
|
| 10:00 am 142 |
Early Clinical Toxicity to Nonnucleoside Reverse Transcriptase Inhibitor-based HAART in a Home-based AIDS Care Program in Rural Uganda
Fatu Forna*1, C Liechty2, P Solberg2, F Asiimwe2, W Were2, J Mermin2, P Behumbiize2, T Tong1, J Brooks1, and P Weidle1
1CDC, Atlanta, GA, US and 2CDC Uganda, Entebbe |
| 10:15 am 143 |
Adverse Events in HIV-infected Patients Receiving ART in a Treatment Program in a Nairobi Slum, Kenya, 2003 to 2005
A Kim1, L Ngan’ga2, D Macharia2, M Wangai3, F Ilako4, A Isavwa2, B Marston2, Kevin M Decock*2, and P Weidle1
1CDC, Atlanta, GA, US; 2CDC Kenya, Nairobi; 3Kenya Ministry of Hlth, Nairobi; and 4African Med Res Fndn, Nairobi, Kenya |
| 10:30 am 144 |
Exposure to PI and NNRTI and Risk of Myocardial Infarction: Results from the D:A:D Study
Nina Friis-Møller*1, P Reiss2, W El-Sadr3, A D'Arminio Monforte4, R Thiébaut5, S De Wit6, R Weber7, E Fontas8, M Law9, A Phillips10, and and the D:A:D Study Group
1Copenhagen HIV Prgm, Hvidovre, Denmark; 2HIV Monitoring Fndn, Academic Med Ctr, Univ of Amsterdam, The Netherlands; 3CPCRA, Columbia Univ, Harlem Hosp, New York, NY, US; 4ICONA, L Sacco Hospital, University of Milan, Milan, Italy; 5Bordeaux Univ Hosp, INSERM U593, France; 6Ctr Hosp Univ St Pierre, Brussels, Belgium; 7Univ Hosp, Zürich, Switzerland; 8Ctr Hosp Univ Nice, Hosp de l'Archet, France; 9Australian HIV Observational Database, Natl Ctr in HIV Epidemiology and Clin Res, Sydney; and 10Royal Free and Univ Coll Med Sch, London, UK |
| 10:45 am 145 |
3-year Follow-up of Carotid Intima-media Thickness in HIV-infected and Uninfected Adults: ACTG 5078
Judith Currier*1, M Kendall2, K Henry3, F Torriani4, J Conley5, B Alston-Smith6, M Basar7, K Mickelberg8, Y Li9, H Howard9, and ACTG 5078 Study Team
1Univ of California CARE Ctr, Los Angeles, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Minnesota, Minneapolis, US; 4Univ of California, San Diego, US; 5Univ of Washington, Seattle, US; 6Div of AIDS, NIAID,, NIH, DHHS, Rockville, MD, US; 7Frontier Sci & Tech Res Fndn, Buffalo, NY, US; 8Univ of Pennsylvania, Philadelphia, US; and 9Univ of Southern California, Los Angeles, US |
| 11:00 am 146 |
The Safety and Efficacy of Fish Oil in Combination with Fenofibrate in Subjects on ART with Hypertriglyceridemia Who Had an Incomplete Response to Either Agent Alone: Results of ACTG A5186
John Gerber*1, D Kitch2, J Aberg3, R Zackin2, S Charles4, E Hogg5, E Acosta6, E Connick1, D Wohl7, C Fichtenbaum8, and ACTG A5186 Team
1Univ of Colorado Hlth Sci Ctr, Denver, US; 2Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3New York Univ, NY, US; 4Frontier Sci & Tech Res Fndn, Amherst, NY, US; 5Social & Sci Systems, Silver Spring, MD, US; 6Univ of Alabama at Birmingham, US; 7Univ of North Carolina at Chapel Hill, US; and 8Univ of Cincinnati Med Ctr, OH, US |
| 11:15 am 147 |
Effects of Metformin and Rosiglitazone on Body Composition in HIV-infected Patients with Hyperinsulinemia and Elevated Waist/Hip Ratio: A Randomized, Placebo-controlled Trial
Kathleen Mulligan*1,2, Y Yang3, S Koletar4, D Wininger4, R Parker3, B Alston-Smith5, M Basar6, S Grinspoon7,8, and ACTG Protocol 5082 Team
1Univ of California, San Francisco, US; 2San Francisco Gen Hosp, CA, US; 3Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 4Ohio State Univ, Columbus, US; 5NIAID, NIH, DHHS, Bethesda, MD, US; 6Frontier Sci & Tech Res Fndn, Amherst, NY, US; 7Harvard Sch of Publ Hlth, Boston, MA, US; and 8Massachusetts Gen Hosp, Boston, US |
| 11:30 am 148 |
A Randomized Placebo-controlled Trial of Metformin for the Treatment of HIV Lipodystrophy
Rakhi Kohli*, C Wanke, S Gorbach, and A Shevitz
Tufts Univ Sch of Med, Boston, MA, US |
| 11:45 am 149 |
Effects of Physiologic Testosterone Supplementation on Fat Mass and Distribution in HIV-infected Men with Abdominal Obesity: ACTG 5079
Cecilia Shikuma*1, R Parker2, F Sattler3, B Alston4, R Haubrich5, T Umbleja2, S Bhasin6, and AIDS Clin Trials Group Protocol A5079 Study Team
1Univ of Hawaii, Honolulu, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3David Geffen Sch of Med, Univ of California, Los Angeles Med Ctr, US; 4NIAID, NIH, DHHS, Bethesda, MD, US; 5Univ of California, San Diego, US; and 6Boston Univ Sch of Publ Hlth, MA, US |
| 12:00 pm 150 |
Randomized, Placebo Controlled Trial of Valganciclovir to Prevent CMV End-organ Disease among HIV-infected Subjects with Detectable Plasma CMV DNA PCR: ACTG 5030
David Wohl*1, M Kendall2, J Andersen2, C Crumpacker3, S Spector4, J Feinberg5, B Alston-Smith6, S Owens7, S Chafey8, and M Jacobson9
1Univ of North Carolina at Chapel Hill, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Beth Israel Deaconess Hosp, Boston, MA, US; 4Univ of California, San Diego, US; 5Univ of Cincinnati Med Ctr, OH, US; 6DAIDS, NIH, Bethesda, MD, US; 7Frontier Sci & Tech Res Fndn, Amherst, MA, US; 8UCLA ISAP/ Project Flow, San Francisco, CA, USA; and 9Univ of California, San Francisco, US |
| 12:15 pm 151LB |
Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized Double-Blind Placebo-Controlled Trial (ANRS 113) with 130 patients
L Slama1, E Lanoy2, M A Valentin2,3, J P Bastard1,4, A Chermak2, A Boutekatjirt3, D William-Faltaos3, J Capeau1,4, D Costagliola2, and Willy Rozenbaum*1,5
1Hosp Tenon, Paris, France; 2INSERM U720, Hosp Pitie-Salpetriere, Paris, France; 3Hosp Pitié-Salpétrière, Paris, France; 4INSERM U680, Paris, France; and 5Hosp Saint Louis, Paris, France |
|
